Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2002-07-01
2009-06-02
Marvich, Maria (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C536S024100, C536S024200, C424S093200
Reexamination Certificate
active
07541179
ABSTRACT:
Recombinant lentiviral vectors having a region encoding a functional β-globin gene; and large portions of the β-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of β-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including β-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than un-transformed cells allows selection by treatment of the cells with the corresponding drug.
REFERENCES:
patent: 5126260 (1992-06-01), Tuan et al.
patent: 5610053 (1997-03-01), Chung et al.
patent: 5631162 (1997-05-01), LeBoulch et al.
patent: 5834256 (1998-11-01), Finer et al.
patent: 5858740 (1999-01-01), Finer et al.
patent: 5981276 (1999-11-01), Sodroski et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 6013516 (2000-01-01), Verma et al.
patent: 6090608 (2000-07-01), Oppenheim et al.
patent: 6110666 (2000-08-01), Grosveld et al.
patent: 6218187 (2001-04-01), Finer et al.
patent: 6294165 (2001-09-01), Lever et al.
patent: 6312682 (2001-11-01), Kingsman et al.
patent: 6428953 (2002-08-01), Naldini et al.
patent: 6444421 (2002-09-01), Chung
patent: 6524851 (2003-02-01), Ellis
patent: 6544771 (2003-04-01), Rivière et al.
patent: 6642043 (2003-11-01), Bertino et al.
patent: WO 97/33988 (1997-09-01), None
Sorrentino et al, Localization and characterization of the DNase I-hypersensitive site II (HS II) enhancer. A critical regulatory element within the beta-globin locus-activating region, Ann NY Acad Sci, 1990;612:141-51.
Collis et al, Definition of the minimal requirements within the human beta-globin gene and the dominant control region for high level expression, EMBO J, Jan. 1990;9(1):233-40.
Molete et al, Sequences flanking hypersensitive sites of the beta-globin locus control region are required for synergistic enhancement, MCB, May 2001;21(9):2969-80.
Genbank NG-000007, priority date Jun. 19, 2006, downloaded Jul. 24, 2006.
NG—000007 (GI:13907843),Homo sapiensgenomic beta globin region on chormosome 11, U.S. National Library of Medicine, Bethesda, MD, USA, May 2001, accessed by PTO on Mar. 2, 2007.
Ryan et al, A single erythroid-specific DNAse I super-hypersensitive site activates high levels of human b-globin gene expression in transgenic mice, Genes and Development, vol. 3, pp. 314-323; see entire document).
Melton et al, Stability of HPRT marker gene expression at different gene-targeted loci: observing and overcoming a position effect, Nucleic Acids Research, 1997, vol. 25, No. 19 3937-3943.
Dzierzak et al., Lineage-specific expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells., 1988, pp. 35-41, vol. 331.
Kalberer et al., Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human β-globin in engrafted mice, PNAS, 2000, pp. 5411-5415, vol. 97, No. 10,
May et al., Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene, Blood, 2002, pp. 1902-1908, vol. 99, No. 6.
Raftopoulos et al., Long-Term Transfer and Expression of the Human β-Globin Gene in a Mouse Transplant Model, Blood, 1997, pp. 3414-3422, vol. 90, No. 9.
Rivella et al., Genetic Treatment of Severe Hemoglobinopathies: The Combat Against Transgene Variegation and Transgene Silencing, Seminars in Hematology, 1998, pp. 112-125, vol. 35, No. 2.
Sabatino et al., Long-term expression of γ-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human γ-globin gene . . . , PNAS, 2000, pp. 13294-13299, vol. 97, No. 24.
Dull et al. (1998) J. Virol. 72:8463-8471, “A Third-Generation Lentiviirus Vector with a Conditional Packaging System”.
Naldini et al. (1996) Science 272:263-267, “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector”.
Sadelain et al. (1995) Proc. Natl. Acad. Sci. 92:6728-6732, “Generation of a high-titer retroviral vector capable of expressing high levels of the human β-globin gene”.
Zufferey et al., “Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery”, Journal of Virology, Dec. 1998, vol. 72, No. 12, pp. 9873-9880.
Gatlin et al. “In Vitro Selection of Lentivirus Vector-Transduced Human CD34+ Cells.” Human Gene Therapy 11: 1949-1957 (2000).
Sadelain “Genetic Treatment of the Haemogloinopathies Recombinations and New Combinations.” British Journal of Haematology 98: 247-253 (1997).
Tisdale et al. “Towards Gene Therapy of Disorders of Golbin Synthesis.” Seminars in Hematology 38:4 382-392 (2001).
Rivella et al. “Globin Gene Transfer: a Paradigm for Transgenic Regulation and Vector Safety.” Gene Therapy and Regulation 00:0; 1-27 (2003).
Sadelain et al. Issues in the Manufacture and Transplantation of Genetically Modified Hematopoietic Stem Cells. Current Opinion in Hematology 7: 364-377 (2000).
Huang. et al., “Nonadditivity of Mutational Effects at the Folate Binding Site ofEscherichia coliDihydrofolate Reductase”,Biochemistry, vol. 33, No. 38, pp. 11576-11585, 1994.
Ercikan et al., “Effect of codon 22 mutations on substrate and inhibitor binding for human dihydrofolate reductase”,Chemistry and Biology of Pteridines and Folates, pp. 515-519, 1993.
May, et al., “Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin”,Nature, vol. 406, pp. 82-86, Jul. 6, 2000.
D. Bodine, “Globin Gene Therapy: One (Seemingly) Small Vector Change, One Giant Leap in Optimism”,Molecular Therapy, vol. 2, No. 2, pp. 101-102, Aug. 2000.
Bertino Joseph
May Chad
Rivella Stefano
Sadelain Michel
Edwards Angell Palmer & & Dodge LLP
Lauro, Esq. Peter C.
Marvich Maria
Memorial Sloan-Kettering Cancer Center
LandOfFree
Vector encoding human globin gene and use thereof in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vector encoding human globin gene and use thereof in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vector encoding human globin gene and use thereof in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4077522